| Previous Close | 59.20 |
| Open | 59.10 |
| Bid | 59.29 x 0 |
| Ask | 59.31 x 0 |
| Day's Range | 58.65 - 59.38 |
| 52 Week Range | 49.31 - 80.91 |
| Volume | 89,938 |
| Avg. Volume | 163,939 |
| Market Cap | 3.284B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | 32.10 |
| EPS (TTM) | 1.85 |
| Earnings Date | Jun. 02, 2021 - Jun. 07, 2021 |
| Forward Dividend & Yield | 0.64 (1.08%) |
| Ex-Dividend Date | May 14, 2021 |
| 1y Target Est | 75.40 |
- The Motley Fool
$1,000 in This Underrated Tech Stock Would Be Worth $27,000 Today!
Underrated tech stocks like Enghouse Systems (TSX:ENGH) have been creating value for decades and deserve closer attention. The post $1,000 in This Underrated Tech Stock Would Be Worth $27,000 Today! appeared first on The Motley Fool Canada.
- Simply Wall St.
Is It Too Late To Consider Buying Enghouse Systems Limited (TSE:ENGH)?
While Enghouse Systems Limited ( TSE:ENGH ) might not be the most widely known stock at the moment, it saw significant...
- CNW Group
Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages
SINGAPORE, March 22, 2021 /CNW/ -- Xylonix, a Singapore-based biotech company, has developed a new immunity drug (010DS-Zn) that demonstrates potential for treating a variety of solid cancers and COVID-19's post-recovery complications, which include heart damage, diabetes and multi-system inflammatory syndrome in children (MIS-C). This research was recently submitted as a preprint publication on bioRxiv.
